-transparent.png){kind=logo}
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones. 1997
Research and Development Center, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, USA.
Modification of the non-nucleoside inhibitor of HIV-1 reverse transcriptase nevirapine (Viramune) by incorporation of a 2-indolyl substituent confers activity against several mutant forms of the enzyme.
Related Publications
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
February 1994,
The Journal of antimicrobial chemotherapy,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
January 2004,
Current topics in medicinal chemistry,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
March 1995,
The Journal of infectious diseases,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
July 2002,
Antimicrobial agents and chemotherapy,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
January 2004,
Current topics in medicinal chemistry,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
November 1998,
Medicina clinica,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
January 2004,
Molecular pharmacology,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
March 1999,
Antiviral chemistry & chemotherapy,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
August 1994,
FEBS letters,
T A Kelly, and
D W McNeil, and
J M Rose, and
E David, and
C K Shih, and
P M Grob
January 2010,
Current medicinal chemistry,
